Project Details
Description
Social science has a long-standing interest in the pharmaceutical industry and its relations with the health system. A key area of concern is the large money sums paid or donated to other health system actors that could allow drug companies to convert their unrivalled financial resources into power over clinical and policy decisions. This internationally collaborative project employs a wealth of available payment data to map power relations involving the industry and medical associations and patient organisations – two actors with key roles in the health system. Informed by sociological and policy research, we examine the nature, structure, and determinants of payments; and their possible effects on the ‘industry-medical-patient complex’ within a global context. The project comprises a combination of light-touch country cases from Europe, Japan and the developing world and in-depth studies of three European countries - UK, Sweden and Latvia. The light-touch cases will involve Social Network Analysis of payment data. The in-depth cases will deploy also regression analyses of payments and other publicly available data, and thematic analysis of interviews with representatives of companies and payment recipients which will be sampled purposively based on their varying levels of inter-connectedness. The project will provide a novel theoretical and methodological toolbox for studying the nature and distribution of power which can inform research on other industries and sectors
| Status | Finished |
|---|---|
| Effective start/end date | 2021/01/01 → 2025/12/31 |
Collaborative partners
- Lund University (lead)
- University of Bath
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
-
SDG 16 Peace, Justice and Strong Institutions
Subject classification (UKÄ)
- Sociology (excluding Social Work, Social Anthropology, Demography and Criminology)
-
Unknowns of drug company payment disclosure: why the UK needs payment transparency legislation
Ozieranski, P., Rickard, E. & Mulinari, S., 2026, In: BMJ Evidence-Based Medicine. 31, 1, p. 7-12Research output: Contribution to journal › Article › peer-review
Open Access -
Pharmaceutical company promotional payments to English general practices: longitudinal study
Mulinari, S., Malik, M., Larkin, J., Elsharkawy, M., Fahey, T., Moriarty, F. & Ozieranski, P., 2025 Aug 8, (E-pub ahead of print) In: BJGP open.Research output: Contribution to journal › Article › peer-review
Open Access -
Self-regulation of UK's pharmaceutical industry
Ozieranski, P., Mulinari, S., Colombo, C. & Mintzes, B., 2025 May 28, In: BMJ (Clinical research ed.). 389, p. r1065Research output: Contribution to journal › Debate/Note/Editorial